Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598449 · ClinicalTrials.gov registry record · Phase 4
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
A Phase 4 study of Dravet Syndrome (DS) and Children Under 2 Years, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06598449: Recruiting Phase 4 study of Dravet Syndrome (DS) and Children Under 2 Years, sponsored by University of Colorado, Denver.
NCT06598449 is a Phase 4 study of Dravet Syndrome (DS) and Children Under 2 Years that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 12 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06598449, a Phase 4 study of Dravet Syndrome (DS) and Children Under 2 Years, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
Dravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in the first year of life with prolonged seizures, often hemiclonic and in the setting of fever or temperature changes such as getting in or out of bath water. Many anti-seizure medications are sodium channel blockers and exacerbate seizures in this patient population. This creates some limitations in medication choices for this patient population. Recently fenfluramine was approved for use in Dravet syndrome for people 2 years and older. Randomized studies demonstrated a 74.9% reduction of convulsive motor seizures compared to 19.2% in the placebo group. Additionally, 16% of children treated with fenfluramine were seizure free. Fenfluramine is likely to be as effective in children under the age of 2 years. The current study has proposed a treatment protocol to allow access to fenfluramine for children under 24 months of age.
Primary Outcome
A description of the percentage of participants that have at least one adverse event.
Conditions Studied
Interventions
- DRUG fenfluramine
Study Locations (3)
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
What NCT06598449 shows while recruiting
NCT06598449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Dravet Syndrome (DS) appearing as the primary indexed condition, and to 1 intervention - of which fenfluramine is the first listed.
NCT06598449 reports a single indexed study location in California, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06598449 about?
NCT06598449 is a clinical study titled "Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age". Dravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in the first year of life with prolonged seizures, often hemiclonic and in the setting of fever or temp...
What is the current status of trial NCT06598449?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2024-10-22. Estimated completion is 2027-07.
What conditions does trial NCT06598449 study?
This clinical trial studies the following conditions: Dravet Syndrome (DS), Children Under 2 Years.
What interventions are being tested in trial NCT06598449?
The interventions under investigation include: fenfluramine (DRUG).
Who is sponsoring clinical trial NCT06598449?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598449 being conducted?
This trial has 3 study locations across California, Colorado, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome (DS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06598449's enrollment target sits among peer trials
12 1914th of 2000 higher than 70 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI